Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study

About 40% of patients who received a combination of Bristol-Myers Squibb Co's immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer (NSCLC) were alive after two years, according to data presented at a medical meeting on Saturday.

from Reuters: Health News https://ift.tt/2nvQw5e